SCHEMBL3490174

SCHEMBL3490174

O=C(CCc1cccc2c1[nH]c1ccccc12)ON1C(=O)CCC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERAP1 Q9NZ08 1/20 0.38
PSMB8 P28062 1/20 0.38
PSMB5 P28074 1/20 0.38
PARP14 Q460N5 6/20 0.37
MAPT P10636 4/20 0.37
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
EGFR P00533 1/20 0.36
SRC P12931 1/20 0.36
CYP19A1 P11511 1/20 0.36
CYP11B1 P15538 1/20 0.36
AHR P35869 1/20 0.36
JAK2 O60674 1/20 0.36
TP53 P04637 1/20 0.36
HTT P42858 1/20 0.36
KLK7 P49862 1/20 0.36
PBRM1 Q86U86 1/20 0.35
POLB P06746 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
KIF11 P52732 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7869140 0.81 KMT2A (0.56) MAPTKMT2AMEN1HTTPOLB
SCHEMBL21664524 0.80 CDYL (0.49) PSMB8PSMB5TDP1KDM4E
SCHEMBL20562275 0.79 EGFR (0.56) ERAP1PARP14MAPTKMT2AMEN1
SCHEMBL5409417 0.76 PSMB8 (0.41) PSMB8PSMB5POLBALDH1A1
SCHEMBL573807 0.76 KDM4E (0.54) PARP14MAPTKMT2AMEN1EGFR
SCHEMBL30421102 0.74 EGFR (0.55) PARP14MAPTEGFRSRCJAK2
SCHEMBL1233101 0.74 CYP1A2 (0.62) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL27535389 0.73 NAAA (0.58) MAPTKMT2AMEN1TDP1ALDH1A1
SCHEMBL17781261 0.71 SMN1; SMN2 (0.37) PSMB8PSMB5MAPTKMT2AMEN1
SCHEMBL436079 0.71 TDP1 (0.54) PSMB8PSMB5MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304520-B2 Labeled fusion protein THE UNIVERSITY OF TOKYO (JP) 2012-11-06 US disclosed
US-20100105882-A1 MOLECULAR MODULE THE UNIVERSITY OF TOKYO (JP) 2010-04-29 US disclosed
EP-2098538-A1 MOLECULAR MODULE The University of Tokyo (JP) 2009-09-09 EP disclosed
US-20050118605-A9 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation ISIS PHARMACEUTICALS, INC. 2005-06-02 US disclosed
US-20050037370-A1 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation BAKER BRENDA F (US) 2005-02-17 US disclosed
US-20050032069-A1 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation ISIS PHARMACEUTICALS, INC. 2005-02-10 US disclosed
WO-2004044245-A1 OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE AND GUANINE AND THEIR USE IN GENE MODULATION ISIS PHARMACEUTICALS, INC. (US) 2004-05-27 WO disclosed
EP-0644890-B1 OLIGONUCLEOTIDE-POLYAMIDE CONJUGATES HOWARD FLOREY INST OF BR EX PH (AU) 2001-12-05 EP disclosed
EP-0383803-B1 OLIGONUCLEOTIDE-POLYAMIDE CONJUGATES HOWARD FLOREY INST OF (AU) 2000-05-03 EP disclosed
EP-0972779-A2 Oligonucleotide-polyamide conjugates HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 2000-01-19 EP disclosed
EP-0644890-A4 OLIGONUCLEOTIDE-POLYAMIDE CONJUGATES. FLOREY HOWARD INST (AU) 1996-03-27 EP disclosed
EP-0644890-A1 OLIGONUCLEOTIDE-POLYAMIDE CONJUGATES HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 1995-03-29 EP disclosed
EP-0366685-B1 NUCLEOSIDE DERIVATIVES FLOREY HOWARD INST (AU) 1994-10-19 EP disclosed
WO-1993024511-A1 OLIGONUCLEOTIDE-POLYAMIDE CONJUGATES HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 1993-12-09 WO disclosed
EP-0366685-A4 NUCLEOSIDE DERIVATIVES 1991-03-20 EP disclosed
EP-0383803-A4 OLIGONUCLEOTIDE-POLYAMIDE CONJUGATES 1991-03-20 EP disclosed
EP-0383803-A1 OLIGONUCLEOTIDE-POLYAMIDE CONJUGATES HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 1990-08-29 EP disclosed
EP-0366685-A1 NUCLEOSIDE DERIVATIVES. FLOREY HOWARD INST (AU) 1990-05-09 EP disclosed
WO-1989003849-A1 OLIGONUCLEOTIDE-POLYAMIDE CONJUGATES HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY (AU) 1989-05-05 WO disclosed
WO-1988010264-A1 NUCLEOSIDE DERIVATIVES HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY (AU) 1988-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050037370-A1 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation RNMT, RRBP1, G3BP1 ERAP1 2591/4885PSMB8 780/4885PSMB5 1466/4885
US-20050118605-A9 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation RNMT, RRBP1, G3BP1 ERAP1 2591/4885PSMB8 780/4885PSMB5 1466/4885
US-20050032069-A1 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation RNMT, RRBP1, G3BP1 ERAP1 2591/4885PSMB8 780/4885PSMB5 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.